Cargando…
EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232720/ http://dx.doi.org/10.1016/j.jval.2022.04.295 |
| _version_ | 1784735651419127808 |
|---|---|
| author | Paladio Hernández, JÁ Godina-Ortiz, BA Lara-Terrazas, A |
| author_facet | Paladio Hernández, JÁ Godina-Ortiz, BA Lara-Terrazas, A |
| author_sort | Paladio Hernández, JÁ |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9232720 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92327202022-06-27 EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico Paladio Hernández, JÁ Godina-Ortiz, BA Lara-Terrazas, A Value Health Article Published by Elsevier Inc. 2022-07 2022-06-25 /pmc/articles/PMC9232720/ http://dx.doi.org/10.1016/j.jval.2022.04.295 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Paladio Hernández, JÁ Godina-Ortiz, BA Lara-Terrazas, A EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico |
| title | EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico |
| title_full | EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico |
| title_fullStr | EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico |
| title_full_unstemmed | EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico |
| title_short | EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico |
| title_sort | ee43 budget impact analysis of favipiravir (avigan®) for the treatment of patients with confirmed infection with sars-cov2 in mexico |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232720/ http://dx.doi.org/10.1016/j.jval.2022.04.295 |
| work_keys_str_mv | AT paladiohernandezja ee43budgetimpactanalysisoffavipiraviraviganforthetreatmentofpatientswithconfirmedinfectionwithsarscov2inmexico AT godinaortizba ee43budgetimpactanalysisoffavipiraviraviganforthetreatmentofpatientswithconfirmedinfectionwithsarscov2inmexico AT laraterrazasa ee43budgetimpactanalysisoffavipiraviraviganforthetreatmentofpatientswithconfirmedinfectionwithsarscov2inmexico |